AltheaDx | GenomeWeb

AltheaDx

The funding comes several months after the drug metabolism testing company withdrew a planned $74.3 million initial public offering. 

As part of the deal, AltheaDx's IDgenetix genetic testing will be integrated into Sinfonia's medication therapy management programs.

In an SEC document, the company said that current terms were not attractive enough for it to continue with a public offering. 

The molecular diagnostics firm anticipates fetching between $12 and $14 per share in its IPO for net proceeds of $52.2 million at the midpoint price of $13 per share. 

The firm offers a portfolio of genetic tests to help clinicians tailor treatments for patients suffering from cardiovascular disease, neuropsychiatric disorders, and pain. 

BioTheranostics Nicolas Barthelemy its new president and CEO. He succeeds Richard Ding, who will remain chairman of the board of bioTheranostics in addition to heading the Asia Pacific operations for parent company bioMérieux.

NEW YORK (GenomeWeb) – AltheaDx's suite of pharmacogenetic tests, called IDgenetix, has been approved by the New York Department of Health, enabling the molecular diagnostics firm to sell the tests in all 50 US states.

NEW YORK (GenomeWeb) – AltheaDx has received accreditation from the College of American Pathologists, the San Diego firm announced today.

NEW YORK (GenomeWeb News) – Life Technologies has added 11 new members from the US and Canada to its Ion AmpliSeq Exome Certified Service Provider program, the company said today.

Life Technologies has named both Asuragen and AltheaDx as authorized customer service providers for sequencing on its Ion Torrent PGM platform.

Pages

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.